SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Hepatitis -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (18)5/20/2002 11:30:45 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 312
 
Thanks Tuck.

Need to do DD on the safety issue.

"However, the LFTs returned to >40% above pre-treatment levels in 3/8 IDN-6556 & 1/3 Pbo pats after dosing. LFTs returned to baseline by 14 days post therapy; no clinical sequelae were seen."

Miljenko